Pilots killed in Southend Airport plane crash named
They were captain Danny Marco Franken and first officer Floris Christiaan Rhee, said flight operator Zeusch Aviation.
They are believed to be Dutch.
The chartered plane, which had taken a patient to the UK for treatment, crashed shortly after take-off at the airport on 13 July.
It's thought the patient had been dropped off and the aircraft was heading back to base in the Netherlands.
Two passengers, a female nurse and a male doctor, also died.
Zeusch Aviation boss Marco Rietvelt said the pilots were "highly skilled".
"Their passion for flying was matched by their dedication to their colleagues and the important missions they carried out," said a statement.
"We are all deeply shocked and saddened by this tragic loss.
"Our priority is to support the families of those lost, as well as our employees, during this incredibly difficult time.
"We are also fully committed to assisting the authorities in their ongoing investigation."
The nurse who died was named in reports as 31-year-old Maria Fernanda Rojaz Ortiz, originally from Chile, and the doctor was named as German national Dr Matthias Eyl, 46.
The UK's Air Accidents Investigation Branch is investigating.
Read more from Sky News:
John Johnson, who was at the airport with his wife and children, said the Beechcraft Super King Air 200 crashed soon after take off.
"It took off and about three or four seconds [later] it started to bank heavily to its left, and then within a few seconds of that happening, it more or less inverted and crashed just head first into the ground," he said.
The pilots had waved at his family moments earlier as they taxied the plane to the take-off position, Mr Johnson said.
Zeusch Aviation is based at Lelystad Airport in the Netherlands.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Eli Lilly raising GLP-1 prices abroad raises more questions about US pricing: BofA analyst
Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other European countries, in response to President Trump's push to normalize pricing in peer developed nations. The effort, known as Most Favored Nations pricing, has been a goal of Trump's since his first term. He has doubled down on the efforts this year, giving pharma companies 60 days to implement changes in pricing in what he deems "freeloading" nations. The US drug economy differs from European and other developed nations, which rely on the government to negotiate prices with drugmakers, resulting in lower prices globally. "While we agree that the costs for breakthrough medicines should be more fairly shared across developed countries, we must also address the underlying structural issues in the US that have contributed to high drug prices. The US system is complex and opaque," Lilly said in a statement Thursday. The stock was up 1% in trading Friday. Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would almost double its price. In a note to clients Friday, Bank of America Securities research analyst Tim Anderson questioned who would actually be impacted by the raised prices. "LLY has announced it will raise GLP-1 pricing in the UK by a healthy margin (a doubling of price, but it's unclear to whom this higher price realistically applies). It expects to do something similar in other European countries (but worth appreciating: in most European markets, there aren't price agreements in place between GLP-1 manufacturers and governments, meaning these are out-of-pocket spending markets)," Anderson wrote. Ultimately, whether or not the move results in lower US prices remains a question, though Anderson believes it likely will not. "Does this mean it will actually cut the price on the GLP-1s in the US (and on other medicines)? To us, the answer is quite likely no, or at least, not in a way that creates P&L [profit and loss planning ] risk," he wrote. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Andrew Flintoff backs campaign to increase helipads at hospitals
Andrew 'Freddie' Flintoff has backed a campaign to help more hospitals get helipads after his own experience of medical air support following his car crash at a Top Gear test track. In December 2022, Flintoff sustained severe injuries while filming at the Dunsfold Aerodrome in Surrey for an episode of BBC show Top Gear. The former international cricketer was airlifted to St George's Hospital in Tooting – a major trauma centre. The helipad at the hospital was funded by a campaign with the Helicopter Emergency Landing Pads (Help) Appeal. As he backed the campaign, Flintoff said: 'When I was airlifted, that helipad wasn't just a safe spot to land on the hospital roof, it was a vital step in giving me a second chance as I had immediate access to the specialist care which helped saved my life. 'As every cricket pitch has a wicket, every hospital that needs one should have a helipad.' The Help Appeal said that there have been 30,000 landings on the 32 NHS hospital helipads funded by the charity across the country. It has also funded 23 major upgrades at other hospital helipads. The charity is aiming to fund 40 new and upgraded helipads. Robert Bertram, chief executive of the Help Appeal, said: 'We are incredibly grateful to have Freddie's support, especially knowing that his life was saved thanks, in part, to a Help Appeal-funded helipad. His story highlights exactly why the charity's work is so vital – seconds count in a medical emergency and that helipad made all the difference. 'Freddie's backing brings invaluable awareness to the importance of rapid access to emergency care for everyone, everywhere.' Sir Keith Porter, emeritus professor of clinical traumatology at the University of Birmingham, said the charity plays a 'crucial part' in getting patients to the right hospital at the right time. He added: 'Helicopter Emergency Medical Services have the ability to deliver critical care teams at or close to the side of a patient and then to transport them to the most appropriate hospital for their clinical needs, in the case of injury, usually a major trauma centre. 'Minutes count, particularly for patients with life-threatening bleeding, where the extra journey time can make the difference between life and death. 'The Help Appeal, by funding on-site helipads, helps facilitate the prompt delivery of patients directly into the emergency department with a trolley-push from the landing site.' Flintoff also recently visited the NHS staff who cared for him after the accident at St George's Hospital. He praised health workers in the NHS as 'superheroes' and described the aftermath of the crash as the 'the lowest I've ever been'. The 47-year-old praised the 'expertise, love and compassion' shown by staff at the hospital during his time of need. During a documentary about the accident, Flintoff described how he used the split-second decision-making from his cricketing days to try to reduce the impact of the crash. He said he was 'pulled face-down on the runway' for about 50 metres under the car. The former England star said he thought he had died in the accident. For months after the crash, Flintoff disappeared from public view and would leave his house only for medical appointments His recovery has been documented in a documentary, Flintoff, streamed on Disney+.
Yahoo
5 hours ago
- Yahoo
Why Eli Lilly (LLY) Stock Is Up Today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.2% in the afternoon session after the stock extended its positive momentum partly fueled by reports of major insider buying by top executives, including the CEO, which is often seen as a strong vote of confidence. Additionally, news that the company has signed a multi-billion dollar deal with an AI health tech company (Superluminal) to discover and develop new obesity medicines also contributed to the positive sentiment. Finally, the company's decision to increase the price of its popular diabetes and weight-loss drug Mounjaro in the UK, in response to US political pressure, was also seen as a positive for future revenue. After the initial pop the shares cooled down to $705.51, up 3.1% from previous close. Is now the time to buy Eli Lilly? Access our full analysis report here, it's free. What Is The Market Telling Us Eli Lilly's shares are not very volatile and have only had 9 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The previous big move we wrote about was 2 days ago when the stock gained 3.1% on the news that reports of significant insider buying by top executives, including the CEO, sent the stock rebounding from a recent selloff. The move came after regulatory filings on Tuesday revealed that several top executives, including CEO David Ricks, had purchased nearly $2.9 million worth of company stock. Ricks alone acquired over $1 million in shares, a move investors often interpret as a strong vote of confidence from leadership. This buying activity follows a significant selloff last week, where the stock dropped about 14% due to disappointing trial data for an oral obesity pill. The insider purchases are seen as a signal that management considers the stock undervalued after the recent decline and believes the market overreacted, providing a catalyst for Wednesday's rebound. Eli Lilly is down 9.3% since the beginning of the year, and at $705.51 per share, it is trading 26.5% below its 52-week high of $960.02 from August 2024. Investors who bought $1,000 worth of Eli Lilly's shares 5 years ago would now be looking at an investment worth $4,656. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
